# Initiation and Titration of Amaryl

Study · id `cardio:ct-nct01144728` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01144728](<https://clinicaltrials.gov/study/NCT01144728>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01144728

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

## Technical summary

Registry record NCT01144728. Allocation not applicable; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 172 participants (enrolled count; ClinicalTrials.gov record NCT01144728, source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01144728, source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)
- Primary completion: 2010-12 (actual) (ClinicalTrials.gov record NCT01144728, source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)
- Completion: 2010-12 (actual) (ClinicalTrials.gov record NCT01144728, source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)
- Countries: Kazakhstan (ClinicalTrials.gov record NCT01144728, source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01144728-2011-01-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Initiation and Titration of Amaryl
- Acronym: AMIT KZ
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): GLIMEPIRIDE + METFORMIN
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 7c5ce01fd7c2eaedf3b635d24ff3d2cfc4284df4f64f96072e3c6bd4095176c6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
